Shares shifted sharply lower as Krystal Biotech dropped 6.8% to $318.01 after posting second-quarter results that forced investors to weigh strong profits against a top-line shortfall. The company earned $1.79 per diluted share, beating Wall Street's $1.70 estimate, but product revenue of $119.2 million fell short of the $122.3 million consensus. For a one-product company approaching $1 billion in cumulative sales, that gap matters — it tests confidence in the growth curve that justifies a premium valuation.
Germany's Pricing Fight Dented the Top Line
The quarter included a full quarter of conservative accounting reserves tied to ongoing pricing negotiations in Germany, which reduced reported European net revenue even as actual product shipments grew.
Management said German demand was growing in "double digits" before that reserve, and expects negotiations to wrap up by the third quarter, with the accounting drag largely resolved by Q4. In other words, real-world demand may be stronger than the headline number suggests — but until pricing is locked in, investors are flying partly blind on the international story.
The U.S. Business Keeps Punching Above Its Weight
U.S. net revenue hit $91.6 million, and the company has now surpassed 730 reimbursement approvals, exceeding its original target of reaching 60% of diagnosed patients with the rare skin disease dystrophic epidermolysis bullosa.
Gross margins held at roughly 95% , meaning nearly every new dollar of revenue flows to the bottom line. That's the engine funding everything else.
A Packed Catalyst Calendar Could Reset the Narrative
Launches in Spain and Italy remain on track for later this year, and the company expects data readouts from multiple pipeline programs — including treatments targeting eye complications, lung cancer, and cystic fibrosis — in the second half of 2026.
Analysts remain broadly constructive, with 9 buy and 2 hold ratings.
Citi recently raised its price target to $386.
What Shareholders Should Watch
The Street now expects Q3 revenue of roughly $140 million and full-year sales near $521 million. Clearing the German pricing overhang and executing the Spain/Italy launches will determine whether this sell-off was a buying opportunity or the start of a slower growth chapter. With $1.1 billion in cash , Krystal has the balance sheet to absorb near-term friction — but patience has limits when a stock trades at a premium built on uninterrupted momentum.